SynthesisBioMed research international2018
Clinical Outcomes after Liver Transplantation for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis.
Synthesis in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical Outcomes after Liver Transplantation for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis.BioMed research international · 2018Pooled it
- Terlipressin in paediatric hepatorenal syndrome-acute kidney injury (HRS-AKI).Pediatric nephrology (Berlin, Germany) · 2026Review
- Kidney safety net utilization after liver transplant for acute alcohol-associated hepatitis.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Hepatorenal Syndrome-Novel Insights into Diagnostics and Treatment.International journal of molecular sciences · 2023Review
- Advances in the diagnosis and management of hepatorenal syndrome: insights into HRS-AKI and liver transplantation.eGastroenterology · 2023Review
- Main factors influencing long-term outcomes of liver transplantation in 2022.World journal of hepatology · 2023Review
- Long-term renal outcomes comparison between patients with chronic kidney disease and hepatorenal syndrome after living donor liver transplantation.Frontiers in surgery · 2023Article
- Management of hepatorenal syndrome in liver cirrhosis: a recent update.Therapeutic advances in gastroenterology · 2022Review
- Hepatorenal syndrome in acute-on-chronic liver failure with acute kidney injury: more questions requiring discussion.Gastroenterology report · 2021Review
- Epidemiology and Prognostic Significance of Rapid Response System Activation in Patients Undergoing Liver Transplantation.Journal of clinical medicine · 2021Article
- Impact of Palliative Care Services on Treatment and Resource Utilization for Hepatorenal Syndrome in the United States.Medicines (Basel, Switzerland) · 2021Article
- Global strategy for the diagnosis and management of acute kidney injury in patients with liver cirrhosis.United European gastroenterology journal · 2021Review
- A Review for the Practicing Clinician: Hepatorenal Syndrome, a Form of Acute Kidney Injury, in Patients with Cirrhosis.Clinical and experimental gastroenterology · 2021Review
- Acute kidney injury: prediction, prognostication and optimisation for liver transplant.Hepatology international · 2020Review
- The Hepato-Cardio-Renal Axis in Cirrhosis: Hemodynamic and Mechanistic Insights, Diagnostic Biomarkers, and Expanding Therapeutic Horizons.Discoveries (Craiova, Romania)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsHepatorenal syndrome (HRS) decreases survival of cirrhotic patients. The outcomes of HRS after liver transplantation (LT) were inconsistently reported. We conducted a systematic review and meta-analysis study to estimate the post-LT rates of death and HRS reversal.
methodsA thorough search of literatures was performed on PubMed, Scopus, and conference abstracts for reports on post-LT survival and HRS reversal. Data for the posttransplant rates of HRS reversal, death, and acute rejection were extracted. The rates were pooled using inverse variance method if there was no heterogeneity between studies. Otherwise, the random effect model was applied.
resultsTwenty studies were included. Pooling HRS reversal rates indicated high heterogeneity with a pooled rate of 0.834 (95% CI: 0.709-0.933). The pooled overall death rates for HRS and non-HRS after LT were 0.25 (95% confidence interval (CI): 0.18-0.33) and 0.19 (95% CI: 0.14-0.26). The risk ratio of death between HRS and non-HRS patients was 1.29 (95% CI: 1.14-1.47,
conclusionsHRS is reversible in about 83% of patients after LT. However, the posttransplant mortality rate of HRS patients is still increased.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.